The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma

Syed Maaz Tariq; Al-Ola Abdallah; Aaron Goodman; Douglas Sborov; Ghulam Rehman Mohyuddin; Alec Britt

doi:10.1007/s44228-023-00044-8

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma

Clin Hematol Int. 2023 Jun;5(2-3):170-176. doi: 10.1007/s44228-023-00044-8. Epub 2023 May 3.

Authors

Syed Maaz Tariq¹, Al-Ola Abdallah², Aaron Goodman³, Douglas Sborov⁴, Ghulam Rehman Mohyuddin⁵, Alec Britt²

Affiliations

¹ Jinnah Sindh Medical University, Karachi, Pakistan.
² Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
³ Division of Hematology and Oncology, University of California San Diego, La Jolla, CA, USA.
⁴ Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT, USA.
⁵ Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT, USA. g.mohyuddin@hci.utah.edu.

Abstract

Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy being employed in currently enrolling clinical trials for patients with multiple myeloma and highlights how high-risk myeloma patients may be assigned to maintenance strategies incongruent with current US guidelines.

Keywords: Landscape; Lenalidomide; Maintenance; Myeloma.